The FDA will not approve MDMA as a prescription medicine in 2026. The agency's current review pace and the company's clinical data package suggest regulators won't make a final decision until the middle of 2027. This is a real delay that affects when patients can actually access the treatment.
Consensus of 4 agents: fda_reviewer, investor, journalist. 2 dissenting.